JR Gralow
About
JR Gralow is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research.
According to data from OpenAlex, JR Gralow has authored 34 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 13 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Cancer Research. Recurrent topics in JR Gralow's work include Bone health and treatments (10 papers), Breast Cancer Treatment Studies (10 papers) and Cancer Treatment and Pharmacology (9 papers). JR Gralow is often cited by papers focused on Bone health and treatments (10 papers), Breast Cancer Treatment Studies (10 papers) and Cancer Treatment and Pharmacology (9 papers). JR Gralow collaborates with scholars based in United States, Canada and South Africa. JR Gralow's co-authors include ML Disis, H. Bernhard, Steven Gillis, N. Davidson, Robin Zoň, Melody Cobleigh, Tamara Shenkier, Scott D. Ramsey, Gabriel N. Hortobágyi and D. F. Hayes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.
In The Last Decade
JR Gralow
34 papers receiving 777 citations
Peers
JR Gralow
Sam Litwin United States
K. Witter Germany
P L Stern United Kingdom
Jianping Yang New Zealand
Cecilia Rietz United States
Carmela La Mendola Italy
R Tubbs United States
Alfons J. van den Eertwegh Netherlands
Juliane S. Walz Germany
Corazon dela Rosa United States
Citations per year, relative to JR Gralow JR Gralow (= 1×)
peers
Sam Litwin
Countries citing papers authored by JR Gralow
Since
Specialization
Citations
This map shows the geographic impact of JR Gralow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JR Gralow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JR Gralow more than expected).
Fields of papers citing papers by JR Gralow
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by JR Gralow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JR Gralow. The network helps show where JR Gralow may publish in the future.
Co-authorship network of co-authors of JR Gralow
This figure shows the co-authorship network connecting the top 25 collaborators of JR Gralow. A scholar is included among the top collaborators of JR Gralow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JR Gralow. JR Gralow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Miao, Jieling, A. Stopeck, Paul Thompson, et al.. (2019). Abstract P1-17-03: Statin use, site of recurrence, and survival among post-menopausal women taking bisphosphonates as adjuvant therapy for breast cancer (SWOG S0307). Cancer Research. 79(4_Supplement). P1–17.
2.
Albain, KS, et al.. (2018). Abstract PD5-07: A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226. Cancer Research. 78(4_Supplement). PD5–7.
3.
Hayes, D. F., et al.. (2014). Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. JNCI Journal of the National Cancer Institute. 106(4). dju034–dju034.
4.
Nováková, Alena, X. Chai, JR Gralow, et al.. (2013). Abstract P4-01-02: The role of FLT PET early assessment of response to endocrine therapy for early stage breast cancer. Cancer Research. 73(24_Supplement). P4–1.
5.
Coleman, RE, Michael Gnant, T.J. Powles, et al.. (2013). Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. Cancer Research. 73(24_Supplement). S4–7.
6.
Gralow, JR, et al.. (2012). Abstract P6-04-03: Changes in breast tumor metabolism and estradiol binding as measured by FES PET in patients treated with the histone deacetylace inhibitor vorinostat and aromatase inhibitor therapy. Cancer Research. 72(24_Supplement). P6–4.
7.
Perez, EA, et al.. (2012). Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study. Cancer Research. 72(24_Supplement). PD10–4.
8.
McMahon, Don, et al.. (2012). Abstract P6-12-03: Effects of high dose of bisphosphonate therapy on bone microarchitecture of the peripheral skeleton in women with early stage breast cancer. Cancer Research. 72(24_Supplement). P6–12.
9.
Carlson, Josh J., Scott D. Ramsey, Patricia A. Deverka, et al.. (2011). PCN9 VALUE OF RESEARCH ANALYSES IN RESEARCH PRIORITIZATION OF CANCER GENOMIC APPLICATIONS. Value in Health. 14(3). A156–A156.
10.
Budd, G. Thomas, Halle C. F. Moore, Timothy J. Hobday, et al.. (2011). First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 1004–1004.
11.
Lembersky, BC, Louis Fehrenbacher, CI Falkson, et al.. (2011). S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.. Cancer Research. 71(24_Supplement). S2–3.
12.
González-Angulo, Ana M., JR Gralow, Funda Meric‐Bernstam, et al.. (2011). SWOG S1007: A phase III, randomized clinical trial of standard adjuvant endocrine therapy with or without chemotherapy in patients with one to three positive nodes, hormone receptor (HR)-positive, and HER2-negative breast cancer with recurrence score (RS) of 25 or less.. Journal of Clinical Oncology. 29(15_suppl). TPS104–TPS104.
13.
Gralow, JR, et al.. (2011). OT1-03-01: A Randomized Phase III Clinical Trial of Standard Adjuvant Endocrine Therapy +/− Chemotherapy in Patients (pts) with 1–3 Positive Nodes, Hormone Receptor (HR)-Positive and HER2−Negative Breast Cancer with Recurrence Score (RS) of 25 or Less: SWOG S1007.. Cancer Research. 71(24_Supplement). OT1–3.
14.
Vogel, C. L., K. Bloom, Howard A. Burris, et al.. (2011). P1-07-02: Discordance between Central and Local Laboratory HER2 Testing from a Large HER2−Negative Population in VIRGO, a Metastatic Breast Cancer Registry.. Cancer Research. 71(24_Supplement). P1–7.
15.
Kurland, Brenda F., et al.. (2009). DCE-MRI and dynamic FDG PET to monitor breast cancer response to neoadjuvant sunitinib in patients with locally-advanced breast cancer.. Cancer Research. 69(2_Supplement). 6006–6006.
16.
Fizazi, Karim, Allan Lipton, Xavier Mariette, et al.. (2008). Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: Final results of a randomized, phase II study. Journal of Clinical Oncology. 26(15_suppl). 3596–3596.
17.
Zoň, Robin, et al.. (2006). A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100. European Journal of Cancer Supplements. 4(2). 47–47.
18.
Coleman, R., JR Gralow, R. Bell, & A. Lipton. (2004). Zoledronic acid for the prevention of bone metastases in patients with breast cancer. European Journal of Cancer Supplements. 2(3). 74–75.
19.
Goodwin, J. Wendall, Jeffrey K. Giguere, Karen L. Hoelzer, et al.. (2001). Double blind phase III trial of placebo (P) vs. megestrol acetate (MA) 20 mg vs. MA 40 mg as treatment for symptoms of ovarian failure in breast cancer survivors: Initial results of Southwest Oncology Group S9626. Breast Cancer Research and Treatment. 69(3).
20.
Disis, ML, et al.. (1996). Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood. 88(1). 202–210.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sam Litwin Breakdown of academic impact, for papers by K. Witter Breakdown of academic impact, for papers by P L Stern Breakdown of academic impact, for papers by Jianping Yang Breakdown of academic impact, for papers by Cecilia Rietz Breakdown of academic impact, for papers by Carmela La Mendola Breakdown of academic impact, for papers by R Tubbs Breakdown of academic impact, for papers by Alfons J. van den Eertwegh Breakdown of academic impact, for papers by Juliane S. Walz Breakdown of academic impact, for papers by Corazon dela Rosa